Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

Condition:   Squamous Cell Cancers of the Head and Neck
Interventions:   Drug: cetuximab;   Drug: afatinib
Sponsors:   Aarti Bhatia;   National Comprehensive Cancer Network;   Boehringer Ingelheim
Not yet recruiting - verified November 2016

http://ift.tt/2ghi8SM